Black Diamond Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
BDTX$1.60-14.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Black Diamond Therapeutics, Inc. Condensed Consolidated Statements of Stockholders' Equity (Unaudited)(in thousands, except share data) | ||||||
|---|---|---|---|---|---|---|
| Common stock · Additionalpaid-in capital · Accumulated other comprehensive income (loss) · Accumulated deficit · Totalstockholders’equity | ||||||
| Shares · Par Value | ||||||
| BALANCE - December 31, 2025 | 57,138,057 | $8 | $576,842 | $101 | $(464,740) | $112,211 |
| Vesting of restricted stock units | 225,000 | — | — | — | — | — |
| Surrender of shares for taxes | (74,307) | — | (185) | — | — | (185) |
| Stock-based compensation | 13,024 | — | 1,447 | — | — | 1,447 |
| Unrealized gain (loss) on investments | — | — | — | (137) | — | (137) |
| Net loss | — | — | — | — | (9,036) | (9,036) |
| BALANCE - March 31, 2026 | 57,301,774 | 8 | 578,104 | (36) | (473,776) | 104,300 |
| Exercise of common stock options | 127,707 | — | 217 | — | — | 217 |
| Stock-based compensation | 16,868 | — | 1,511 | — | — | 1,511 |
| Unrealized gain (loss) on investments | — | — | — | (32) | — | (32) |
| Net loss | — | — | — | — | (9,905) | (9,905) |
| BALANCE - June 30, 2026 | 57,446,349 | 8 | 579,832 | (68) | (483,681) | 96,091 |
| Issuance of common stock related to ESPP | 7,398 | — | 12 | — | — | 12 |
| Stock-based compensation | 14,508 | — | 2,228 | — | — | 2,228 |
| Unrealized gain (loss) on investments | — | — | — | (241) | — | (241) |
| Net loss | — | — | — | — | (10,012) | (10,012) |
| BALANCE - September 30, 2026 | 57,468,255 | $8 | $582,072 | $(309) | $(493,693) | $88,078 |
| The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. | ||||||
| Black Diamond Therapeutics, Inc. Condensed Consolidated Statements of Stockholders' Equity (Unaudited)(in thousands, except share data) | ||||||
|---|---|---|---|---|---|---|
| Common stock · Additionalpaid-in capital · Accumulated other comprehensive income (loss) · Accumulated deficit · Totalstockholders’equity | ||||||
| Shares · Par Value | ||||||
| BALANCE - December 31, 2024 | 56,644,655 | $7 | $570,361 | $24 | $(487,107) | $83,285 |
| Issuance of common stock related to ESPP | 17,567 | — | 32 | — | — | 32 |
| Stock-based compensation | 14,494 | — | 1,700 | — | — | 1,700 |
| Unrealized gain (loss) on investments | — | — | — | (43) | — | (43) |
| Net income | — | — | — | — | 56,542 | 56,542 |
| BALANCE - March 31, 2025 | 56,676,716 | 7 | 572,093 | (19) | (430,565) | 141,516 |
| Exercise of common stock options | 12,608 | — | 26 | — | — | 26 |
| Vesting of restricted stock units | 270,000 | — | — | — | — | — |
| Surrender of shares for taxes | (84,081) | — | (142) | — | — | (142) |
| Stock-based compensation | 11,696 | — | 1,777 | — | — | 1,777 |
| Unrealized gain (loss) on investments | — | — | — | (6) | — | (6) |
| Net loss | — | — | — | — | (10,561) | (10,561) |
| BALANCE - June 30, 2025 | 56,886,939 | 7 | 573,754 | (25) | (441,126) | 132,610 |
| Exercise of common stock options | 41,166 | 1 | 120 | — | — | 121 |
| Issuance of common stock related to ESPP | 7,174 | — | 13 | — | — | 13 |
| Stock-based compensation | 8,134 | — | 1,739 | — | — | 1,739 |
| Unrealized gain (loss) on investments | — | — | — | 167 | — | 167 |
| Net loss | — | — | — | — | (8,498) | (8,498) |
| BALANCE - September 30, 2025 | 56,943,413 | $8 | $575,626 | $142 | $(449,624) | $126,152 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.